Risvutatug rezetecan cut the risk of progression or death by 67% vs gemcitabine/docetaxel in heavily pretreated R/R osteosarcoma in ARTEMIS-011.
|Articles|October 6, 2016
Cancer in Cavemen?
Author(s)Bobby Lazzara, MD
In this Medical News Minute, developed exclusively for Cancer Network, Dr. Bobby Lazzara discusses a recent case report of a 1.7-million-year-old osteosarcoma found in an extinct human lineage.
Advertisement
In this Medical News Minute, developed exclusively for Cancer Network, Dr. Bobby Lazzara discusses a recent case report of a 1.7-million-year-old osteosarcoma found in an extinct human lineage.
Advertisement
Related to this article
Two-year MANEUVER data show durable, deepening responses and sustained gains in pain, stiffness, and function with pimicotinib in TGCT.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves SC Amivantamab for Recurrent/Metastatic HNSCC
2
FDA Sets PDUFA Date for Rivoceranib/Camrelizumab Resubmission After Third CRL in Unresectable HCC
3
Sacituzumab Govitecan Efficacy, Safety Debated in First-Line Metastatic TNBC
4
Air Pollution Emerges as Second Leading Risk Factor for Lung Cancer Deaths
5